The Global Health Body Raises Alert Over Acute Shortage of Obesity Medications
Under a tenth of patients eligible to benefit from weight-loss injections including Wegovy can access them, states the global health agency as it issues its first recommendations on the drugs.
With over a billion people worldwide now classified as obese, it is urging broader and more equitable availability to GLP-1 medication.
Per estimates, more than two billion will be living with obesity by 2030 if no action is taken.
"Our latest guidance acknowledges that obesity is a long-term condition that can be managed with comprehensive and lifelong care," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and logistical bottlenecks are major obstacles to widespread availability to the jabs that can help people shift considerable weight, notes the organization.
GLP-1 Therapy Scarcity
Even in the current best projected outlook, the production of GLP-1 therapies might only reach about 100 million people – less than 10% of eligible patients, as stated by the health organization.
The guideline encourages nations and manufacturers to increase access, via approaches like voluntary licensing.
The intellectual property rights on the active ingredient – the core component of the drug Wegovy – is scheduled to end in multiple countries in 2026.
The Way Weight-Loss Injections Function
The injections imitate a body's own hormone to delay gastric emptying, suppress the appetite and increase the sense of being full so users consume fewer calories.
Individuals typically see weight reduction in the initial weeks of commencing the once-weekly jabs.
Evidence indicates patients may see weight return after a year of discontinuing the drug, because their typical food cravings resume.
To be above a healthy weight elevates your likelihood for contracting medical conditions, including diabetes, heart disease, stroke, and some malignancies.
Obesity impacts individuals in all nations and was linked to millions of fatalities worldwide in 2024, according to the health agency.
